Georgiana Surpateanu - Publications

2009-2013 ICSN CNRS, Paris, Île-de-France, France 

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Mounkoro P, Michel T, Benhachemi R, Surpateanu G, Iorga BI, Fisher N, Meunier B. Mitochondrial complex III Q -site inhibitor resistance mutations found in laboratory selected mutants and field isolates. Pest Management Science. PMID 30426681 DOI: 10.1002/Ps.5264  0.491
2018 Nguyen TL, Nokin MJ, Egorov M, Tomé M, Bodineau C, Di Primo C, Minder L, Wdzieczak-Bakala J, Garcia-Alvarez MC, Bignon J, Thoison O, Delpech B, Surpateanu G, Frapart YM, Peyrot F, et al. mTOR inhibition via displacement of phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells. Cancer Research. PMID 30054335 DOI: 10.1158/0008-5472.Can-18-0232  0.524
2014 de Miguel L, Noiray M, Surpateanu G, Iorga BI, Ponchel G. Poly(γ-benzyl-L-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting. International Journal of Pharmaceutics. 460: 73-82. PMID 24211357 DOI: 10.1016/J.Ijpharm.2013.10.048  0.467
2012 Nguyen TB, Lozach O, Surpateanu G, Wang Q, Retailleau P, Iorga BI, Meijer L, Guéritte F. Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases. Journal of Medicinal Chemistry. 55: 2811-9. PMID 22352892 DOI: 10.1021/Jm201727W  0.544
2012 Surpateanu G, Iorga BI. Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors. Journal of Computer-Aided Molecular Design. 26: 595-601. PMID 22180049 DOI: 10.1007/S10822-011-9526-X  0.528
2012 Surpateanu G, Soulé JF, Beau JM, Norsikian S, Iorga BI. Conformational study of glycal-type neuraminidase inhibitors Journal of Carbohydrate Chemistry. 31: 114-129. DOI: 10.1080/07328303.2011.636161  0.523
2008 Goeminne A, Berg M, McNaughton M, Bal G, Surpateanu G, Van der Veken P, De Prol S, Versées W, Steyaert J, Haemers A, Augustyns K. N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase. Bioorganic & Medicinal Chemistry. 16: 6752-63. PMID 18571422 DOI: 10.1016/J.Bmc.2008.05.056  0.388
2008 Goeminne A, McNaughton M, Bal G, Surpateanu G, Van Der Veken P, De Prol S, Versées W, Steyaert J, Haemers A, Augustyns K. Synthesis and biochemical evaluation of guanidino-alkyl-ribitol derivatives as nucleoside hydrolase inhibitors. European Journal of Medicinal Chemistry. 43: 315-26. PMID 17582660 DOI: 10.1016/J.Ejmech.2007.03.027  0.399
2007 Joossens J, Ali OM, El-Sayed I, Surpateanu G, Van der Veken P, Lambeir AM, Setyono-Han B, Foekens JA, Schneider A, Schmalix W, Haemers A, Augustyns K. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. Journal of Medicinal Chemistry. 50: 6638-46. PMID 18052026 DOI: 10.1021/Jm700962J  0.433
2007 Goeminne A, McNaughton M, Bal G, Surpateanu G, Van der Veken P, De Prol S, Versées W, Steyaert J, Apers S, Haemers A, Augustyns K. 1,2,3-Triazolylalkylribitol derivatives as nucleoside hydrolase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 2523-6. PMID 17317181 DOI: 10.1016/J.Bmcl.2007.02.017  0.442
2006 Joossens J, Van der Veken P, Surpateanu G, Lambeir AM, El-Sayed I, Ali OM, Augustyns K, Haemers A. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position. Journal of Medicinal Chemistry. 49: 5785-93. PMID 16970403 DOI: 10.1021/Jm060622G  0.429
Show low-probability matches.